Prados, Michael

Oncogenic Signaling Pathways in The Cancer Genome Atlas

Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 3,201

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell

Cancer Genomics and DiagnosticsGene expression and cancer classification

Cited by 2,546

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell

Cancer Cells and MetastasisPluripotent Stem Cells Research

Cited by 2,180

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors

Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine

Glioma Diagnosis and TreatmentHER2/EGFR in Cancer Research

Cited by 1,442

Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas

Smith, J. S., Chang, E. F., Lamborn, K. R., Chang, S. M., Prados, M. D., Cha, S., Tihan, T., VandenBerg, S., McDermott, M. W., & Berger, M. S. (2008) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentOvarian cancer diagnosis and treatment

Cited by 1,283

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 929

Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentCancer survivorship and care

Cited by 902

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer

Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports

Hippo pathway signaling and YAP/TAZCancer-related molecular mechanisms research

Cited by 500

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma

Fontebasso, A. M., Papillon-Cavanagh, S., Schwartzentruber, J., Nikbakht, H., Gerges, N., Fiset, P.-O., Bechet, D., Faury, D., De Jay, N., Ramkissoon, L. A., et al. (2014) · Nature Genetics

Glioma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 465

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute

Glioma Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 465

An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway

Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A. N., Soto, H., Zhu, S., et al. (2011) · Cancer Discovery

Cancer, Lipids, and MetabolismGlioma Diagnosis and Treatment

Cited by 452

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 399

EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy

Guo, D., Prins, R. M., Dang, J., Kuga, D., Iwanami, A., Soto, H., Lin, K. Y., Huang, T. T., Akhavan, D., Hock, M. B., et al. (2009) · Science Signaling

Cancer, Lipids, and MetabolismGlioma Diagnosis and Treatment

Cited by 351

Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma

Rubenstein, J. L., Fridlyand, J., Abrey, L., Shen, A., Karch, J., Wang, E., Issa, S., Damon, L., Prados, M., McDermott, M., et al. (2007) · Journal of Clinical Oncology

CNS Lymphoma Diagnosis and TreatmentLymphoma Diagnosis and Treatment

Cited by 327

Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group

Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., et al. (2007) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentToxin Mechanisms and Immunotoxins

Cited by 325

Temozolomide in the treatment of recurrent malignant glioma

Chang, S. M., Theodosopoulos, P., Lamborn, K., Malec, M., Rabbitt, J., Page, M., & Prados, M. D. (2004) · Cancer

Glioma Diagnosis and TreatmentCancer survivorship and care

Cited by 90